Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Docetaxel used as single-agent treatment in elderly patients with breast cancer
June 30th, 2005
Docetaxel was used as a single-agent treatment in elderly patients with breast cancer. In a recent report, researchers in Spain conducted a study "to assess the efficacy and safety profile of docetaxel, as a single agent, in the treatment of elderly patients with advanced breast cancer. Twenty-eight patients, with a median age of 72 (range 66-84) years, were included in the study and received docetaxel (50-100 mg/m2) every 3-4 weeks as first-or second-line treatment of advanced breast cancer." "Granulocyte colony-stimulating factor (G-CSF) was administered as primary prophylaxis in 97% of cycles. The overall response rate was 50% (95% CI...
Source: Women's Health Weekly (2005-06-30)
|
